What is MultiCASE?
MultiCASE specializes in advanced software solutions tailored for chemical safety assessments across diverse industries. Their offerings, including CASE Ultra, QSAR Flex, and META Ultra, are instrumental in supporting risk assessment strategies for pharmaceutical impurities, nitrosamine assessments, and regulatory compliance. The company's technology aids drug discovery, development, and ensures safety evaluations are conducted efficiently for a global clientele that spans pharmaceutical firms, academic institutions, and sectors such as medical devices, cosmetics, and food additives.
How much funding has MultiCASE raised?
MultiCASE has raised a total of $92K across 1 funding round:
Debt
$92K
Debt (2021): $92K with participation from PPP
What's next for MultiCASE?
With significant Series B/C stage backing, MultiCASE is poised for accelerated growth and market penetration. The substantial expansion capital is expected to fuel further development of their innovative chemical safety evaluation software and broaden their reach within the pharmaceutical and related industries. This strategic financing will likely enable the company to enhance its research processes, strengthen its global support network, and solidify its role in ensuring robust safety evaluations and regulatory adherence.
See full MultiCASE company page
